Overall survival: Patient outcome, therapeutic objective, clinical trial end point, or public health measure?

Journal of Clinical Oncology

Volumn 30, Issue 15, 2012, Pages 1750-1754

  Saad, Everardo D ^a   Buyse, Marc ^b  

^a Dendrix Research   (Brazil)

^b INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RESEARCH; CANCER SURVIVAL; CLINICAL RESEARCH; HUMAN; NEOPLASM; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; HUMANS; NEOPLASMS; PUBLIC HEALTH; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84864004759     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.6359     Document Type: Note

References (66)

1. O'Shaughnessy J, Twelves C, Aapro M: Treatment for anthracycline- pretreated metastatic breast cancer. Oncologist 7:4-12, 2002 (suppl 6)
2. Bonneterre J, Buzdar A, Nabholtz JM, et al: Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92:2247-2258, 2001
3. Mouridsen H, Gershanovich M, Sun Y, et al: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21:2101-2109, 2003 (Pubitemid 46606358)
4. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
5. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
6. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 343:905-914, 2000
7. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004 (Pubitemid 41095110)
8. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004 (Pubitemid 38702844)
9. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004 (Pubitemid 39315317)
10. de Bono JS, Oudard S, Ozguroglu M, et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376:1147-1154, 2010
11. de Bono JS, Logothetis CJ, Molina A, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005, 2011
12. Vermorken JB, Remenar E, van Herpen C, et al: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695-1704, 2007 (Pubitemid 350005151)
13. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006 (Pubitemid 43209104)
14. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 24:4991-4997, 2006 (Pubitemid 46631401)
15. Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376:687-697, 2010
16. Motzer RJ, Hutson TE, Tomczak P, et al: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584-3590, 2009
17. Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281, 2007 (Pubitemid 46849157)
18. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007 (Pubitemid 46089673)
19. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005 (Pubitemid 41058344)
20. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006 (Pubitemid 44917502)
21. Pirker R, Pereira JR, Szczesna A, et al: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 373:1525-1531, 2009
22. Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825, 2011
23. Korn EL, Freidlin B, Abrams JS: Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol 29:2439-2442, 2011
24. Peppercorn JM, Smith TJ, Helft PR, et al: American Society of Clinical Oncology statement: Toward individualized care for patients with advanced cancer. J Clin Oncol 29:755-760, 2011
25. Fleming TR, Rothmann MD, Lu HL: Issues in using progression-free survival when evaluating oncology products. J Clin Oncol 27:2874-2880, 2009
26. Matsuyama R, Reddy S, Smith TJ: Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol 24:3490-3496, 2006 (Pubitemid 46638908)
27. Slevin ML, Stubbs L, Plant HJ, et al: Attitudes to chemotherapy: Comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 300:1458-1460, 1990 (Pubitemid 20195333)
28. Balmer CE, Thomas P, Osborne RJ: Who wants second-line, palliative chemotherapy? Psychooncology 10:410-418, 2001 (Pubitemid 32904005)
29. Bremnes RM, Andersen K, Wist EA: Cancer patients, doctors and nurses vary in their willingness to undertake cancer chemotherapy. Eur J Cancer 31A:1955-1959, 1995 (Pubitemid 26023084)
30. Hirose T, Horichi N, Ohmori T, et al: Patients preferences in chemotherapy for advanced non-small-cell lung cancer. Intern Med 44:107-113, 2005 (Pubitemid 40372688)
31. McQuellon RP, Muss HB, Hoffman SL, et al: Patient preferences for treatment of metastatic breast cancer: A study of women with early-stage breast cancer. J Clin Oncol 13:858-868, 1995
32. Crawford ED, Bennett CL, Stone NN, et al: Comparison of perspectives on prostate cancer: Analyses of survey data. Urology 50:366-372, 1997
33. Smith I: Goals of treatment for patients with metastatic breast cancer. Semin Oncol 33:S2-S5, 2006
34. Johnson JR, Temple R: Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat Rep 69:1155-1159, 1985
35. Ocana A, Amir E, Vera F, et al: Addition of bevacizumab to chemotherapy for treatment of solid tumors: Similar results but different conclusions. J Clin Oncol 29:254-256, 2011
36. Colombel M, Davin JL, Filleul A, et al: Diagnosis and management of advanced hormone-refractory prostate cancer: Results of a practice survey on 301 French urologists [in French]. Prog Urol 14:182-188, 2004 (Pubitemid 38813733)
37. Pazdur R: Endpoints for assessing drug activity in clinical trials. Oncologist 13:19-21, 2008 (suppl 2)
38. Sargent D: General and statistical hierarchy of appropriate biologic endpoints. Oncology (Williston Park) 20:5-9, 2006
39. US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research: Guidance for industry: Clinical trial endpoints for the approval of cancer drugs and biologics. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf
40. Di Leo A, Buyse M, Bleiberg H: Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-11. Ann Oncol 15:545-549, 2004 (Pubitemid 38559586)
41. Di Leo A, Bleiberg H, Buyse M: Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: A critical assessment based on recently reported phase III trials in colorectal and breast cancer. J Clin Oncol 21:2045-2047, 2003
42. Hidalgo M: Pancreatic cancer. N Engl J Med 362:1605-1617, 2010
43. Buyse ME, Squifflet P, Laporte S, et al: Prediction of survival benefits from progression-free survival in patients with advanced non small cell lung cancer: Evidence from a pooled analysis of 2,838 patients randomized in 7 trials. J Clin Oncol 26:428s, 2008 (suppl 15; abstr 8019)
44. Hotta K, Fujiwara Y, Matsuo K, et al: Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer. J Thorac Oncol 4:311-317, 2009
45. Knox JJ: Progression-free survival as endpoint in metastatic RCC? Lancet 372:427-429, 2008
46. Saad ED, Katz A, Buyse M: Overall survival and post-progression survival in advanced breast cancer: A review of recent randomized clinical trials. J Clin Oncol 28:1958-1962, 2010
47. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
48. Fukuoka M, Wu YL, Thongprasert S, et al: Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29:2866-2874, 2011
49. Green S, Benedetti J, Crowley J: Clinical Trials in Oncology. London, United Kingdom, Chapman and Hall, 1997, p 40
50. Tang PA, Bentzen SM, Chen EX, et al: Surrogate end points for median overall survival in metastatic colorectal cancer: Literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 25:4562-4568, 2007 (Pubitemid 350035313)
51. Saad ED, Katz A: Progression-free survival and time to progression as primary end points in advanced breast cancer: Often used, sometimes loosely defined. Ann Oncol 20:460-464, 2009
52. Johnson JR, Williams G, Pazdur R: End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21:1404-1411, 2003 (Pubitemid 46606423)
53. European Medicines Agency: Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man (CHMP/EWP/205/95 rev. 3): Methodological considerations for using progression-free survival (PFS) as primary endpoint in confirmatory trials registration. http://www.ema.europa.eu/docs/en GB/document library/Scientific guideline/2009/12/WC500017736.pdf
54. Yothers G: Toward progression-free survival as a primary end point in advanced colorectal cancer. J Clin Oncol 25:5153-5154, 2007
55. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516, 2011
56. Panageas KS, Ben-Porat L, Dickler MN, et al: When you look matters: The effect of assessment schedule on progression-free survival. J Natl Cancer Inst 99:428-432, 2007 (Pubitemid 47073565)
57. Saad ED, Katz A, Hoff PM, et al: Progression-free survival as surrogate and as true end point: Insights from the breast and colorectal cancer literature. Ann Oncol 21:7-12, 2010
58. Buyse M, Molenberghs G, Burzykowski T, et al: The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 1:49-67, 2000
59. Buyse M, Burzykowski T, Carroll K, et al: Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 25:5218-5224, 2007 (Pubitemid 350232253)
60. Michiels S, Le Maître A, Buyse M, et al: Surrogate endpoints for overall survival in locally advanced head and neck cancer: Meta-analyses of individual patient data. Lancet Oncol 10:341-350, 2009
61. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al: Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 26:1987-1992, 2008
62. Broglio KR, Berry DA: Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 101:1642-1649, 2009
63. Sargent D: What constitutes reasonable evidence of efficacy and effectiveness to guide oncology treatment decisions? Oncologist 15:19-23, 2010 (suppl 1)
64. Fojo T, Grady C: How much is life worth: Cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 101:1044-1048, 2009
65. Miksad RA, Schnipper L, Goldstein M: Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? J Clin Oncol 25:4506-4507, 2007; author reply 4508
66. Grothey A, Sargent D, Goldberg RM, et al: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209-1214, 2004 (Pubitemid 41079833)